Our Mission
Mitodicure is focused on developing oral therapeutics to address significant unmet medical needs in diseases with chronic fatigue.
Our lead clinical candidate, MDC002, is a novel molecule to treat patients with exertional intolerance and post-exertional malaise. We are pursuing a patient-focused approach to build a leading therapeutics company for post-acute infection syndromes and non-infectious chronic fatigue, with an initial focus on ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome).
Leadership
Mitodicure is led by a team with significant drug development experience and supported by leading scientific and clinical advisors in the field.
Harald Pacl
Chief Executive Officer / Co-Founder
Prof. Dr. Harald Pacl, PhD in Organic Chemistry, Master’s degree (diploma) in Business Administration, has been serving as CEO and Managing Director of Mitodicure since 2022. He brings over two decades of leadership experience in the biopharmaceutical industry, combining scientific expertise with strong financial and strategic capabilities. Prior to co-founding Mitodicure, Harald held a series of leadership roles as Senior Director in New Ventures, Strategy, Science Policy, and External Innovation and as R&D CFO at Sanofi in Germany. He led strategic transactions and innovative partnerships, including the BioNTech-Sanofi licensing agreement in 2015. Harald began his career in Finance and Controlling for Production and Manufacturing at Sanofi in 1997. As co-founder and supervisory board member of Accovion GmbH, he contributed to the company’s growth and successful exit. Harald is an honorary professor at Justus Liebig University Giessen, Germany.
Klaus Wirth
Chief Scientific Officer / Co-Founder
Prof. Dr. Klaus Wirth, Medical Doctor, PhD, has been serving as Chief Scientific Officer and Managing Director of Mitodicure since 2022. He was previously Senior Researcher at Sanofi in Germany which he joined in 1984. Klaus worked as a pharmacologist in the fields of cardiovascular, bradykinin antagonism, cerebral blood flow, stroke, heart failure, arrhythmias, sodium-calcium exchanger NCX blockers, endocrinology, diabetes, obstructive sleep apnea (MOS118), dysphagia, and immunology. Approximately 70 patents are attributable to his work, as well as 5 clinical development projects, out of which Firazyr™, a drug for the treatment of acute attacks of hereditary angioedema, has reached the market. Klaus was co-founder of KOSA Pharma GmbH. He is an adjunct professor at the Institute of Pharmacology at Goethe University Frankfurt, Germany.
Scientific Advisors
Volker Geiss, DVM
Toxicology
Former Vice President at Bayer
LinkedIn
Heinz Haenel, Prof., PhD
Project Planning
Former Vice President at Sanofi
LinkedIn
Andreas Meudt, PhD, MBA
Chemistry, Manufacturing and Controls
Former Vice President at Evonik
LinkedIn
Wolfgang Richter, PhD
Drug Metabolism, Pharmacokinetics/-dynamics
Former Distinguished Scientist at Roche
LinkedIn
Bernd Rosenkranz, Prof., MD, PhD
Clinical Development
Former Vice President at Jerini
LinkedIn